If approved, garadicimab will slot into CSL's product line alongside two C1 esterase inhibitor medicines, namely Berinert which is administered by intravenous injection to treat HAE attacks ...

CSL is set to benefit from strong momentum in its Construction Materials segment. However, increasing costs and expenses remain concerning. We recently published a list of 10 Worst Beaten Down ...

If approved, garadicimab will slot into CSL’s product line alongside two C1 esterase inhibitor medicines, namely Berinert, which is administered by intravenous injection to treat HAE attacks ...

It has been about a month since the last earnings report for Carlisle (CSL). Shares have lost about 1.7% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading ...

Carlisle’s total revenues of $1.12 billion missed the consensus estimate of $1.15 billion. The top line decreased 0.4% year over year. For 2024, CSL reported net revenues of $5 billion, which ...

CSL) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257 in the week after its latest half-year results. Revenues of US$8.5b were in line with forecasts ...

Learn More The CSL Ltd (ASX: CSL) share price is down 1.6% to $255.51 per share on Monday. The ASX 200 biotech is in the red today because its shares have begun trading ex-dividend. The CSL share ...

The top line decreased 0.4% year over year. For 2024, CSL reported net revenues of $5 billion, which increased 9.1% year over year. For the year, the company’s adjusted earnings were $20.20 per ...